Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Index is published monthly on basis of weighted average from NASDAQ closing bid prices for 54 stocks: 37 Pharmaceuticals, 11 Diversifieds, 3 Drug Chains and 3 Drug & Medical Supply Wholesalers. Zenith Labs' agreement to co-market generic Dyazide with Ciba-Geigy's Geneva Generics subsidiary once the FDA approves a pending ANDA sent Zenith stock 2-1/4 higher on the last day of September trading. The issue closed the month at 8-1/2. The Sept. 28 announcement by Zenith of the agreement with Geneva and of the pending ANDA for generic Dyazide at FDA was interpreted by some Street watchers as a signal that the Zenith product may be close to an approval. If so, Zenith and Geneva would become the second generic marketer of the diuretic/antihypertensive in the re-opened generic market resulting from the market withdrawals by Bolar and Vitarine last year. Rugby, which had co-marketed the Bolar product, re-entered the generic Dyazide market on Oct. 1 following a deal with former Dyazide patent-holder SmithKline Beecham ("The Pink Sheet" Aug. 27, p. 3). A near-term generic Dyazide approval could provide enough of a boost to spur a full turnaround for Zenith, which completed Chapter 11 reorganization late last year and issued new common stock. So far this year the stock has been on a bumpy road to recovery. Zenith started 1990 trading at 7-1/2, jumped to a high of 9-1/2 in January, fell to a low of 4-1/4 in March, rebounded to 7-1/4 in July and followed the August market down to 6-1/4. Zenith hovered near 6-1/4 until Sept. 27, when it jumped back to 8-1/2. A strong recovery in sales and the benefits of substantially reduced competition in the generic market also appear to be giving Zenith a boost. Through six months of 1990, Zenith's sales were nearly 79% higher, at $26.3 mil., and the company reported earnings of $1.1 mil. compared to a $4.4 mil. loss a year ago. Zenith was the biggest point gainer of the 54 stocks tracked by the F-D-C "OTC" Index and was second in percentage increase behind Taro Vit's 40% jump on a 3/4-point gain to 2-5/8. The monthly index of drug and drug-related stocks fell 6.2% in September, mirroring the Dow Jones Industrials' 6.2% decline and underperforming the S&P 400, which slipped 5.6%. Buoyed by "buy" recommendations from Robertson Stephens and Shearson Lehman analysts, Genetics Institute finished September up 1 at 30-1/4. The recommendations were based on perceptions of the stock's relative value near $30 a share as well as the company's bullish views about the prospects for licensee Chugai/Upjohn's EPO to hit the market in early 1991. The analysts also were optimistic about 1991 marketing approvals for recombinant Factor VIII, which Baxter will market as Recombinate, and GM-CSF, which will be marketed by Schering-Plough and Sandoz. Other September gainers included drug wholesaler Durr-Fillauer (up 1 to 24-1/4), specialty drug firm Jones Medical (up 1-3/8 to 10-7/8), R&D firm Medco Research (up 3/4 to 10) and Chantal (up 1/4 to 1-3/4). Hit hardest in the September skid were Repligen (off 3-5/8 to 5), Enzon (down 1-7/8 to 4-1/8), Agouron (down 2 to 6), Marsam (down 3-7/8 to 12-1/4), and Chattem (off 4-1/2 to 22).

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts